Kenneth Brian Gordon, MD

Chair, Professor

Request an Appointment

Location

Dermatology, Froedtert Bluemound Clinics
601 N. 99th St.
Wauwatosa, WI 53226

Specialties

Dermatology

New & Established Patients Call

(414) 777-7700

Overview

Diseases and Conditions

Inflammatory Skin Disorders
Psoriasis
Psoriatic Arthritis

Treatments and Services

Virtual Visit

Patients Ages Seen

Adult
Senior

Languages

English

Hospital Affiliations

Froedtert Hospital – Milwaukee
Zablocki VA Medical Center – Milwaukee

Board Certifications

Dermatology

Clinic Locations

Dermatology, Froedtert Bluemound Clinics

601 N. 99th St.
Wauwatosa, WI 53226
(414) 805-5320
Get Directions

Biography

Education and Training

Doctor of Medicine - Columbia University College of Physicians and Surgeons - New York, NY (1990)
Residency in Internal Medicine - Beth Israel Hospital - Boston, MA (1990-1993)
Residency in Dermatology - Northwestern University Medical School - Chicago, IL (1993-1997)
Fellowship in Immunology - Northwestern University Medical School - Chicago, IL (1995-1997)

Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial.

(Strober B, Thaçi D, Sofen H, Kircik L, Gordon KB, Foley P, Rich P, Paul C, Bagel J, Colston E, Throup J, Kundu S, Sekaran C, Linaberry M, Banerjee S, Papp KA.) J Am Acad Dermatol. 2023 Jan;88(1):40-51 PMID: 36115523 SCOPUS ID: 2-s2.0-85144040320 09/18/2022
Anti-IL 23 biologics for the treatment of plaque psoriasis.

(Vu A, Ulschmid C, Gordon KB.) Expert Opin Biol Ther. 2022 Dec;22(12):1489-1502 PMID: 36243011 SCOPUS ID: 2-s2.0-85140999891 10/16/2022
Super-response to guselkumab treatment in patients with moderate-to-severe psoriasis: age, body weight, baseline Psoriasis Area and Severity Index, and baseline Investigator's Global Assessment scores predict complete skin clearance.

(Reich K, Gordon KB, Strober B, Langley RG, Miller M, Yang YW, Shen YK, You Y, Zhu Y, Foley P, Blauvelt A.) J Eur Acad Dermatol Venereol. 2022 Dec;36(12):2393-2400 PMID: 35920762 SCOPUS ID: 2-s2.0-85136531215 08/04/2022
Deucravacitinib in moderate-to-severe psoriasis.

(Vu A, Maloney V, Gordon KB.) Immunotherapy. 2022 Nov;14(16):1279-1290 PMID: 36373503 SCOPUS ID: 2-s2.0-85142918537 11/15/2022
Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis: Pooled Results From Phase 2 and Phase 3 Randomized Clinical Trials.

(Gordon KB, Langley RG, Warren RB, Okubo Y, Stein Gold L, Merola JF, Peterson L, Wixted K, Cross N, Deherder D, Thaçi D.) JAMA Dermatol. 2022 Jul 01;158(7):735-744 PMID: 35544084 PMCID: PMC9096693 SCOPUS ID: 2-s2.0-85130365798 05/12/2022
Molecular and clinical effects of selective tyrosine kinase 2 inhibition with deucravacitinib in psoriasis.

(Catlett IM, Hu Y, Gao L, Banerjee S, Gordon K, Krueger JG.) J Allergy Clin Immunol. 2022 Jun;149(6):2010-2020.e8 PMID: 34767869 SCOPUS ID: 2-s2.0-85121371307 11/13/2021
Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis.

(Gordon KB, Lebwohl M, Papp KA, Bachelez H, Wu JJ, Langley RG, Blauvelt A, Kaplan B, Shah M, Zhao Y, Sinvhal R, Reich K.) Br J Dermatol. 2022 Mar;186(3):466-475 PMID: 34652810 PMCID: PMC9298814 SCOPUS ID: 2-s2.0-85119997467 10/16/2021
Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study.

(Crowley JJ, Langley RG, Gordon KB, Pinter A, Ferris LK, Rubant S, Photowala H, Xue Z, Wu T, Zhan T, Beeck S, Shah M, Warren RB.) Dermatol Ther (Heidelb). 2022 Feb;12(2):561-575 PMID: 35050485 PMCID: PMC8850502 01/21/2022
Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial.

(Thaçi D, Strober B, Gordon KB, Foley P, Gooderham M, Morita A, Papp KA, Puig L, Menter MA, Colombo MJ, Elbez Y, Kisa RM, Ye J, Napoli AA, Wei L, Banerjee S, Merola JF, Gottlieb AB.) Dermatol Ther (Heidelb). 2022 Feb;12(2):495-510 PMID: 35025062 PMCID: PMC8850503 01/14/2022
Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study

(Crowley JJ, Langley RG, Gordon KB, Pinter A, Ferris LK, Rubant S, Photowala H, Xue Z, Wu T, Zhan T, Beeck S, Shah M, Warren RB.) Dermatology and Therapy. February 2022;12(2):561-575 SCOPUS ID: 2-s2.0-85123243722 02/01/2022
Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial

(Thaçi D, Strober B, Gordon KB, Foley P, Gooderham M, Morita A, Papp KA, Puig L, Menter MA, Colombo MJ, Elbez Y, Kisa RM, Ye J, Napoli AA, Wei L, Banerjee S, Merola JF, Gottlieb AB.) Dermatology and Therapy. February 2022;12(2):495-510 SCOPUS ID: 2-s2.0-85123098014 02/01/2022
Efficacy, safety, usability, and acceptability of risankizumab 150 mg formulation administered by prefilled syringe or by an autoinjector for moderate to severe plaque psoriasis

(Blauvelt A, Gordon KB, Lee P, Bagel J, Sofen H, Lockshin B, Soliman AM, Geng Z, Zhan T, Alperovich G, Stein Gold L.) Journal of Dermatological Treatment. 2022;33(4):2085-2093 SCOPUS ID: 2-s2.0-85105382915 01/01/2022